| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | FCRL5; CD307; FCRH5; IRTA2; BXMAS1; PRO820 |
| Entrez GeneID | 83416 |
| clone | 2A10H7 |
| WB Predicted band size | 106.4kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD307E (AA: extra 16-158) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD307E(FcRL5)抗体的3篇代表性文献摘要：
1. **"FCRL5 exerts receptor function via JAK/STAT signaling in B-cell malignancies"**
- **作者**: Li FJ, et al.
- **摘要**: 该研究揭示了CD307E(FCRL5)在B细胞淋巴瘤中通过激活JAK/STAT信号通路促进肿瘤细胞存活，其特异性抗体可阻断该通路并诱导凋亡，为靶向治疗提供依据。
2. **"Targeting FCRL5 with CAR-T cells shows efficacy in multiple myeloma models"**
- **作者**: Smithson G, et al.
- **摘要**: 研究团队开发了靶向CD307E的CAR-T细胞疗法，在体外和小鼠多发性骨髓瘤模型中显示出强效抗肿瘤活性，提示其作为新型免疫疗法的潜力。
3. **"Structural basis of FCRL5 recognition by therapeutic antibodies in autoimmune disorders"**
- **作者**: Chen X, et al.
- **摘要**: 通过X射线晶体学解析了CD307E胞外区与治疗性抗体的复合物结构，揭示了抗体特异性结合表位，为优化自身免疫病抗体药物设计提供了结构基础。
注：以上文献信息为示例性内容，实际文献需通过PubMed等数据库检索确认。建议使用关键词"FCRL5"或"CD307E"结合"antibody"、"therapy"等筛选近年研究。
CD307e, also known as Fc receptor-like 5 (FCRL5), is a member of the Fc receptor-like (FCRL) family, which shares structural homology with classical Fc receptors but lacks direct Fc-binding capacity. Expressed predominantly on B lymphocytes, CD307e plays a regulatory role in immune responses. It features extracellular immunoglobulin domains and intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs), suggesting involvement in modulating B cell receptor (BCR) signaling. Studies indicate that CD307e may act as a co-receptor, fine-tuning B cell activation, differentiation, or tolerance through balanced inhibitory and activating signals.
This molecule is of particular interest in immunopathology due to its altered expression in B cell malignancies, autoimmune disorders, and infections. Overexpression has been observed in chronic lymphocytic leukemia (CLL) and multiple myeloma, positioning it as a potential diagnostic biomarker or therapeutic target. Conversely, reduced expression correlates with autoimmune conditions like systemic lupus erythematosus (SLE), hinting at its role in maintaining immune homeostasis.
CD307e-targeting antibodies have emerged as investigational tools in both basic research and clinical development. Therapeutic monoclonal antibodies against CD307e are being explored for hematologic cancers, leveraging its tumor-selective expression. Research continues to unravel its ligand interactions, signaling cascades, and tissue-specific functions, with implications for precision immunotherapy and disease monitoring.
×
